BGM Group Ltd(BGM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.8 | Insider Own | 72.48% | Shs Outstand | 6.0M | Perf Week | 0.06% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.7M | Perf Month | 22.61% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | - | Inst Own | 0.09% | Short Float | 0.22% | Perf Quarter | 4.42% |
| Income | -0.02B | P/S | 2.5 | EPS this Y | - | Inst Trans | - | Short Ratio | 1.04 | Perf Half Y | -9.34% |
| Sales | 0.05B | P/B | 0.15 | EPS next 5Y | - | ROA | -6.58% | Short Interest | 0.01M | Perf YTD | -91.89% |
| Book/sh | 59.55 | P/C | 10.38 | EPS past 3/5Y | - | ROE | -7.3% | 52W High | -97.03% ($302.40) | Perf Year | -96.8% |
| Cash/sh | 0.86 | P/FCF | 82.09 | Sales past 3/5Y | -16.38% -5.39% | ROIC | -5.32% | 52W Low | 39.15% ($6.45) | Perf 3Y | -89.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.66% | Gross Margin | 12.81% | Volatility(W/M) | 17.05% 15.02% | Perf 5Y | -98.34% |
| Dividend TTM | - | EV/Sales | 2.32 | Sales Y/Y TTM | 78.43% | Oper. Margin | -23.42% | ATR (14) | 1.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.65 | EPS Q/Q | 58.37% | Profit Margin | -44.22% | RSI (14) | 52.54 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.25 | Sales Q/Q | 69.76% | SMA20 | 0.06% ($8.97) | Beta | 1.93 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 6.69% ($8.42) | Rel Volume | 0.36 | Prev Close | $8.4 |
| Employees | 471 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -57.79% ($21.27) | Avg Volume(3M) | 0.01M | Price | $8.98 |
| IPO | 2021/1/12 | Option/Short | No/Yes | Trades | 462 | Volume | 2,888 | Change | 6.85% |
💊 BGM Group is a healthcare company listed on the US Nasdaq, building its growth foundation around specialty and generic pharmaceutical businesses. As a micro-cap growth stock seeking to expand its footprint in the pharmaceutical market through enhanced manufacturing capabilities and a broader product portfolio, it is pursuing business diversification to stabilize its revenue structure.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 36% of its average volume.
BGM has weak earning power
Of every $100 in sales, $23.42 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $250. Peers typically go for $197.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #56 of 83 in the industry
Based on market cap of $120M.
FAQ
What kind of company is BGM?
BGM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BGM?
The market cap of BGM is approximately $120M, ranking 4,366 within its sector.
What is the 52-week high and low for BGM?
BGM has recorded a 52-week high of $302.40 and a low of $6.45.
